HER2 overexpression is associated with aggressive BC phenotypes and increased chemoresistance to certain chemotherapeutic agents [75] due to downstream signaling pathways that promote cell survival and proliferation [74,76]. This evidence concerns the gene ERBB2 and breast cancer.